Bio-Sight Capital

FunPep Company Limited is a biotechnology firm based in Tokyo, Japan, specializing in the research and development of pharmaceuticals, cosmetics, and medical devices utilizing functional peptides. Founded in 2013, the company is currently advancing several peptide-based treatments, including SR-0379, aimed at addressing intractable skin ulcers, and FPP003, which is undergoing Phase I/IIa clinical trials for psoriasis in Australia, alongside preclinical studies for ankylosing spondylitis in Japan. Additionally, FunPep is developing FPP004, an antibody-inducing peptide targeted at pollinosis. The company's innovative approach emphasizes the therapeutic potential of peptides across various health-related applications.

FunPep Company Limited is a biotechnology firm based in Tokyo, Japan, specializing in the research and development of pharmaceuticals, cosmetics, and medical devices utilizing functional peptides. Founded in 2013, the company is currently advancing several peptide-based treatments, including SR-0379, aimed at addressing intractable skin ulcers, and FPP003, which is undergoing Phase I/IIa clinical trials for psoriasis in Australia, alongside preclinical studies for ankylosing spondylitis in Japan. Additionally, FunPep is developing FPP004, an antibody-inducing peptide targeted at pollinosis. The company's innovative approach emphasizes the therapeutic potential of peptides across various health-related applications.

JTEC Corporation designs, manufactures, and sells X-ray mirrors for synchrotron facilities in Japan. Its X-ray mirrors are used for study in the pharmaceutical, electronic, material, food, beauty, and other fields. The company also designs, develops, manufactures, and sells automated cell culture systems, as well as automated systems in various fields. JTEC Corporation was founded in 1993 and is headquartered in Ibaraki, Japan.

FunPep Company Limited is a biotechnology firm based in Tokyo, Japan, specializing in the research and development of pharmaceuticals, cosmetics, and medical devices utilizing functional peptides. Founded in 2013, the company is currently advancing several peptide-based treatments, including SR-0379, aimed at addressing intractable skin ulcers, and FPP003, which is undergoing Phase I/IIa clinical trials for psoriasis in Australia, alongside preclinical studies for ankylosing spondylitis in Japan. Additionally, FunPep is developing FPP004, an antibody-inducing peptide targeted at pollinosis. The company's innovative approach emphasizes the therapeutic potential of peptides across various health-related applications.

B-Bridge International -- founded in 2000 and based in Santa Clara, California with branches in Japan -- acts as an incubator to connect the two business ecosystem to increase Japan's presence in the world, by educating companies and entrepreneurs of both cultures.